Drug Profile
Research programme: allergy and asthma vaccines - PYC Therapeutics/Swiss Institute of Allergy & Asthma Research
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Phylogica
- Developer PYC Therapeutics; Swiss Institute of Allergy and Asthma Research
- Class Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Asthma; Hypersensitivity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Allergy in Australia (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Allergy in Switzerland (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in Australia (Parenteral)